![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1524242
¹ß±âºÎÀü Ä¡·á±â±â ½ÃÀå : ±â±â À¯Çüº°, ¿¬·É´ëº°, ¿øÀκ°, ÃÖÁ¾ ¿ëµµº° - ¿¹Ãø(2024-2032³â)Erectile Dysfunction Device Market - By Device Type (Non-Surgical Devices, Surgical Devices), By Age Group (<40, 40 -60 years, >60), By Cause (Diabetes, Neurological disorders, Hypertension), By End-use (Hospitals, Clinics, ASCs) & Forecast, 2024 - 2032 |
¹ß±âºÎÀü Ä¡·á±â±â ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 9.3% ÀÌ»óÀÇ ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
»çȸÀû ±Ý±â¿¡ µµÀüÇÏ°í ¿¸° ´ëȸ¦ ÃËÁøÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ÀÌ´Ï¼ÅÆ¼ºê´Â ³²¼ºµéÀÌ µÎ·Á¿òÀ̳ª ºÎ²ô·¯¿ò ¾øÀÌ ÇÊ¿äÇÑ ÀÇ·á Áö¿øÀ» ¹ÞÀ» ¼ö ÀÖµµ·Ï ÈûÀ» ½Ç¾îÁÝ´Ï´Ù. ÀÌ·¯ÇÑ ¹®ÈÀû ÀüȯÀº °³ÀÎÀÇ °Ç° ¼º°ú¸¦ Çâ»ó½ÃŰ°í ¹ß±âºÎÀü Ä¡·á±â±â ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÕ´Ï´Ù.
¿¹¸¦ µé¾î, 2023³â 11¿ù ¸Á°í¾Ë¿¢½º(MangoRx)´Â ³²¼º °Ç° ÀǽĿ¡ ÃÊÁ¡À» ¸ÂÃá ÀÚ¼± Ä·ÆäÀÎÀ» ½ÃÀÛÇß½À´Ï´Ù. ÀÌ È¸»ç´Â ÇÑ ´Þ µ¿¾È ºê·£µå Á¦Ç° ÆÇ¸Å ¼öÀÍÀÇ 50%¸¦ ´Ù¾çÇÑ ³²¼º °Ç° ¹× À£ºù ÀÚ¼± ´Üü¿¡ ±âºÎÇÒ °ÍÀ» ¾à¼ÓÇß½À´Ï´Ù.
´õ ¸¹Àº ³²¼ºµéÀÌ ÀÚ½ÅÀÇ °í¹ÎÀ» Åоî³õ°í ÀÇ·á ¼ºñ½º¸¦ ÀÌ¿ëÇÒ¼ö·Ï ÀÇ·á±â±â ¹× Ä¡·á¹ýÀ» Æ÷ÇÔÇÑ È¿°úÀûÀÎ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀÔ´Ï´Ù. °á±¹, ¹ß±âºÎÀü Ä¡·á ½ÃÀåÀ» È®´ëÇϰí ȯÀÚ Ä¡·á Àü¹ÝÀ» °³¼±ÇÏ´Â µ¥ ÀÖ¾î ³«ÀÎ Á¦°Å ³ë·ÂÀº Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ °ÍÀÔ´Ï´Ù.
¿Ü°ú¿ë ±â±â ºÐ¾ß´Â 2024³âºÎÅÍ 2032³â±îÁö ³î¶ó¿î CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. À½°æ ÀÓÇöõÆ®¿Í °°Àº ¼ö¼ú±â±¸´Â ¹ß±âºÎÀü¿¡ ´ëÇÑ Àå±âÀûÀÎ ÇØ°áÃ¥À» Á¦°øÇϸç, ´Ù¸¥ Ä¡·á¹ýÀÌ È¿°ú°¡ ¾ø´Â ȯÀÚ¿¡°Ô ¼±È£µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼ö¼ú ±â¼ú ¹× ±â±¸ ¼³°èÀÇ ¹ßÀüÀ¸·Î ÇÕº´Áõ°ú ȸº¹ ½Ã°£ÀÌ ´ÜÃàµÇ°í Ä¡·á °á°ú°¡ °³¼±µÇ°í ÀÖ½À´Ï´Ù. ÀνÄÀÌ °³¼±µÇ°í ¹ß±âºÎÀü¿¡ ´ëÇÑ Æí°ßÀÌ ÁÙ¾îµé¸é¼ ¼º±â´ÉÀ» ȸº¹Çϱâ À§ÇÑ ½ÇÇà °¡´ÉÇÑ ÇØ°áÃ¥À¸·Î ¼ö¼úÀû ¿É¼ÇÀ» °í·ÁÇÏ´Â ³²¼ºµéÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ȯÀÚ¸¦ À§ÇÑ È¿°úÀûÀÌ°í ³»±¸¼º ÀÖ´Â Ä¡·á ¿É¼ÇÀ» ã´Â ÀÇ·áÁø¿¡ ÀÇÇØ µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù.
½Å°æÁúȯ ºÐ¾ß´Â ´Ù¹ß¼º °æÈÁõ(MS), ô¼ö ¼Õ»ó SCI µî ¹ß±âºÎÀüÀ» À¯¹ßÇÒ ¼ö ÀÖ´Â ÁúȯÀÇ È®»êÀ¸·Î ÀÎÇØ 2032³â±îÁö ¹ß±âºÎÀü Ä¡·á±â±â ½ÃÀå¿¡¼ ÁÖ¸ñÇÒ ¸¸ÇÑ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ È¯ÀÚµéÀº ¼º±â´É¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ½Å°æÇÐÀû Ãø¸é°ú ¹ß±â¸¦ ´Þ¼ºÇϰí À¯ÁöÇÏ´Â ½ÅüÀû ´É·Â¿¡ ´ëÇÑ Àü¹®ÀûÀÎ Ä¡·á°¡ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹Àºµ¥, ¹ß±âºÎÀü Ä¡·á ±â±â´Â Á¾ÇÕÀûÀÎ Ä¡·á °èȹ¿¡ Æ÷Ç﵃ ¼ö ÀÖ´Â ºñħ½ÀÀû ¶Ç´Â Àúħ½ÀÀû Ä¡·á ¿É¼ÇÀ» Á¦°øÇϰí, ÀÌ·¯ÇÑ È¯Àڵ鿡°Ô ±Ùº»ÀûÀÎ ½Å°æÇÐÀû »óÅ¿¡µµ ºÒ±¸ÇÏ°í ¼º±â´ÉÀ» ȸº¹ÇÏ°í »îÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö ÀÖ´Â ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.
À¯·´ÀÇ ¹ß±âºÎÀü Ä¡·á±â±â ½ÃÀåÀº 2032³â±îÁö À¯¸ÁÇÑ CAGR·Î Å« ¼ºÀåÀ» ±â·ÏÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. À¯·´ÀÇ °í·ÉÈ¿Í ¹ß±âºÎÀüÀÌ Ä¡·á °¡´ÉÇÑ ÁúȯÀ̶ó´Â Àνİú ¼ö¿ëµµ°¡ ³ô¾ÆÁö¸é¼ ¹ß±âºÎÀü Ä¡·á±â±â¿Í °°Àº È¿°úÀûÀÎ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸¹Àº À¯·´ ±¹°¡µéÀÇ ÀÇ·á ÀÎÇÁ¶ó ¹× »óȯ Á¤Ã¥ÀÇ Çõ½ÅÀ¸·Î ÀÎÇØ ´õ ¸¹Àº »ç¶÷µéÀÌ ÀÌ·¯ÇÑ ±â±â¸¦ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. °Ç° °ü¸®¿Í »îÀÇ Áú¿¡ ´ëÇÑ ¹®ÈÀû °üÁ¡µµ ±â¿©Çϰí ÀÖÀ¸¸ç, ´õ ¸¹Àº ³²¼ºµéÀÌ ´«¿¡ ¶çÁö ¾Ê°í È¿°úÀûÀ¸·Î ¼º±â´ÉÀ» ȸº¹ÇÒ ¼ö ÀÖ´Â ºñħ½ÀÀû Ä¡·á¹ýÀ» ã°í ÀÖ¾î ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
Global Erectile Dysfunction Device Market will indicate over 9.3% CAGR between 2024 and 2032, driven by escalating efforts to destigmatize erectile dysfunction by advocacy groups and healthcare providers globally. By challenging societal taboos and promoting open dialogue, these initiatives empower men to seek necessary medical assistance without fear or shame. This cultural shift enhances individual health outcomes and fuels market growth for erectile dysfunction treatments.
For instance, in November 2023, MangoRx launched a charitable campaign focusing on mens health awareness. The company pledges to donate 50% of sales proceeds from its branded merchandise throughout the month to support various mens health and wellness charities.
As more men feel comfortable discussing their concerns and accessing healthcare services, demand rises for effective solutions, including medical devices and therapies. Ultimately, destigmatization efforts play a crucial role in expanding the market for erectile dysfunction treatments, enhancing overall patient care.
The overall erectile dysfunction device market is classified based on device type, age group, cause, end-use, and region.
The surgical devices segment will register an impressive CAGR from 2024 to 2032. Surgical devices, such as penile implants, offer a long-term solution for ED that may be preferred by patients who have not responded well to other treatments. Moreover, advancements in surgical techniques and device design have improved outcomes, reducing complications and recovery times. As awareness grows and the stigma surrounding ED diminishes, more men are exploring surgical options as a viable solution to restore sexual function. This trend is supported by healthcare providers seeking effective, durable treatment options for their patients.
The neurological disorders sector will seize a notable erectile dysfunction device market share by 2032 because of the prevalence of conditions such as multiple sclerosis MS and spinal cord injuries SCI that can lead to ED. These patients often require specialized treatments that can address both the neurological aspects affecting sexual function and the physical ability to achieve and maintain an erection. ED devices provide non-invasive or minimally invasive options that can be integrated into comprehensive treatment plans, offering these patients a chance to regain sexual function and improve their quality of life despite their underlying neurological conditions.
Europe erectile dysfunction device market will register significant growth, with a promising CAGR through 2032. Europe aging population, coupled with increasing awareness and acceptance of ED as a treatable condition, has fueled demand for effective solutions like ED devices. Innovations in healthcare infrastructure and reimbursement policies in many European countries have made these devices more accessible to a broader demographic. Cultural attitudes toward healthcare and quality of life also contribute, as more men seek out non-invasive treatments that can restore sexual function discreetly and effectively, bolstering market growth.